Google DeepMind Announces AlphaGenome 2 for Single-Cell Genomic Analysis
Google DeepMind has introduced AlphaGenome 2, a next-generation genomic AI model trained on over 107 million single-cell profiles from humans and mice. The new model transitions from tissue-level predictions to high-resolution single-cell analysis, nearly doubling the accuracy of identifying disease-associated genetic variations. This breakthrough allows researchers to pinpoint how DNA mutations affect specific cell types and states, significantly improving our understanding of disease mechanisms and progression. It opens new avenues for targeted biomedical research, drug development, and vaccine response analysis without requiring retraining for unseen cell types. AlphaGenome 2 utilizes a novel conditional model architecture and supports cross-modal data inference, predicting molecular metrics like DNA methylation, histone modifications, and chromatin accessibility. It is currently available for non-commercial research via the AlphaGenome API and through a limited private preview for commercial users.
## BACKGROUND
Genomics is the study of an organism's entire genome, aiming to understand how genes and their regulatory regions dictate biological functions and disease susceptibility. Single-cell profiling and gene expression analysis enable scientists to observe genetic activity and variations at the individual cell level, overcoming the limitations of averaging data across entire tissue samples.